What is the recommended treatment for inflammatory myopathy?

Treatment of Inflammatory Myopathy

For newly diagnosed adult inflammatory myopathy, initiate high-dose prednisone (0.5-1 mg/kg/day, typically 60-80 mg daily) combined immediately with a steroid-sparing immunosuppressive agent—either methotrexate, azathioprine, or mycophenolate mofetil—followed by a structured corticosteroid taper over several months. 1

Initial Treatment Algorithm for Adults

Corticosteroid Regimen

• Start prednisone at 0.5-1 mg/kg/day (typically 60-80 mg daily as a single dose) for 2-4 weeks based on patient response 1
• Begin tapering after initial 2-4 weeks using the following structured schedule 1:
  • Decrease by 10 mg every 2 weeks until reaching 30 mg/day
  • Then decrease by 5 mg every 2 weeks until reaching 20 mg/day
  • Then decrease by 2.5 mg every 2 weeks until reaching 10 mg/day
  • At 10 mg/day, slow taper to 1 mg every 2-4 weeks until completion

Concurrent Steroid-Sparing Agent (Choose One)

No single agent has proven superiority over others, so selection depends on patient-specific factors 1:

Methotrexate 1

• Start at 15 mg orally once weekly with 1 mg daily folic acid supplementation
• Titrate to target dose of 25 mg weekly within 3-6 months
• Critical monitoring: Baseline liver function tests, hepatitis B and C antibodies, screening for preexisting lung disease
• Key contraindications/precautions: Counsel women of childbearing potential on reliable contraception (teratogenic); avoid excessive alcohol use
• Common adverse effects: GI symptoms, stomatitis (manageable with higher folic acid doses or leucovorin rescue)
• Important caveat: Interstitial lung disease is NOT an absolute contraindication, though MTX-induced pneumonitis is a rare concern

Azathioprine 1

• Mandatory pre-treatment: Check thiopurine methyltransferase (TPMT) level to screen for enzyme deficiency (risk of severe myelosuppression)
• Target dose: 2 mg/kg ideal body weight in divided doses
• Start at 25-50 mg weekly, increase by 25-50 mg weekly until goal dose reached
• Common adverse effects: Nausea, loose stools; less common: fever, liver toxicity

Mycophenolate Mofetil 1

• Start at 500 mg twice daily
• Increase by 500 mg weekly until reaching 1000 mg twice daily
• Particularly effective for severe dermatomyositis with skin disease 1

Timeline Expectations

• Steroid-sparing agents are slow-acting: Expect 3-6 months to reach full efficacy 1
• This delayed onset justifies the concurrent initiation with corticosteroids rather than sequential therapy

Treatment for Severe or Refractory Disease

For patients with severe myositis, extensive extramuscular organ involvement (especially interstitial lung disease, cardiac involvement, or dysphagia), or refractory disease despite initial therapy, escalate to 1:

• High-dose intravenous methylprednisolone PLUS one of the following:
  • Intravenous immunoglobulin (IVIG): Proven efficacy in refractory dermatomyositis with improvements in skin and muscle disease activity 2
  • Rituximab: Evidence supports use in certain myositis-specific antibody subgroups 3
  • Cyclophosphamide: For severe organ involvement
  • Cyclosporine: Alternative for refractory cases

Juvenile Dermatomyositis (JDM) Specific Approach

For uncomplicated JDM, the regimen differs slightly 1, 4:

• Corticosteroids: 2 mg/kg/day up to maximum 60 mg daily, with taper after 2-4 weeks based on response
• Subcutaneous methotrexate: 15 mg/m² once weekly, initiated at onset of treatment (subcutaneous route preferred in pediatrics)
• For severe JDM: Use same escalation strategy as adults with high-dose methylprednisolone plus IVIG, cyclophosphamide, rituximab, or cyclosporine 1, 4

Critical Monitoring and Multidisciplinary Considerations

Disease Activity Assessment

• Use validated tools regularly: Manual Muscle Test (MMT8), Childhood Myositis Assessment Scale (CMAS) for muscle strength and function 4
• MRI with T2-weighted/STIR sequences: Useful for diagnosis and monitoring disease activity 4
• Emerging biomarkers: Interleukin-6 and type 1 interferon-regulated genes may serve as disease activity indicators 1, 2

Extramuscular Organ Screening

At diagnosis, evaluate for 1, 4:

• Pulmonary: Pulmonary function tests, chest X-ray, high-resolution CT if interstitial lung disease suspected (major cause of mortality) 5
• Cardiac: ECG and echocardiography (arrhythmias, diastolic dysfunction common; severe disease less typical but important) 4, 6
• Dysphagia: Formal swallow assessment including speech/language therapy evaluation, videofluoroscopy 1, 4
• Malignancy screening: Age-appropriate cancer screening (dermatomyositis has malignancy association) 1
• Myositis-specific and myositis-associated antibodies: Guide prognosis, organ involvement risk, and potentially therapy selection 1, 7, 8

Infection Prophylaxis

Consider trimethoprim-sulfamethoxazole prophylaxis for patients on high-dose immunosuppression, as it reduces risk of Pneumocystis jirovecii pneumonia AND other severe infections, particularly respiratory tract infections 9

Common Pitfalls to Avoid

1. Delaying steroid-sparing agent: Always start immunosuppressive therapy concurrently with corticosteroids, not sequentially, to minimize cumulative steroid exposure and long-term toxicity 1

2. Tapering corticosteroids too rapidly: Follow the structured taper schedule; premature reduction commonly leads to disease flare 1

3. Missing TPMT testing before azathioprine: Failure to check can result in life-threatening myelosuppression 1

4. Overlooking interstitial lung disease: This is a major cause of morbidity and mortality; screen at baseline and monitor closely 5

5. Assuming inclusion body myositis responds to immunosuppression: This subtype typically does NOT respond to standard immunosuppressive therapy and requires different management approach 7, 8

6. Neglecting physical therapy: Supervised, individualized exercise programs should complement pharmacological treatment to improve muscle performance 3

Emerging Therapies

For refractory disease, novel approaches under investigation include 2:

• JAK inhibitors targeting interferon pathway
• CD19-targeting CAR T-cell therapy for B-cell depletion
• Therapies targeting specific T-cell subsets

These represent promising options when conventional immunosuppression fails, though they remain largely investigational 2.